IMPRINT BIO Trademark

Trademark Overview


On Friday, October 4, 2024, a trademark application was filed for IMPRINT BIO with the United States Patent and Trademark Office. The USPTO has given the IMPRINT BIO trademark a serial number of 98785816. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Tuesday, July 29, 2025. This trademark is owned by Imprint Labs, LLC. The IMPRINT BIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Creating, designing and improving of datasets, namely data analysis, computational modeling, and data compiling for training artificial intelligence (AI) models and large language models (LLM) to learn patterns and make predictions and data models and training data for identifying druggable targets, antibody sequences and cell therapies in the fields of immunology, immunomics, immunotherapy, psychiatry, neurology, allergy, and infectious disease; Providing temporary use of online non-downloadable software for searching, reviewing, analyzing, testing, predicting, inferring, reconstructing, organizing, screening and sharing data, methodologies, and protocols in the fields of immunology, immunomics, immunotherapy, psychiatry, neurology, allergy, and infectious disease; Providing temporary use of online non-downloadable software for searching, reviewing, analyzing, testing, predicting, inferring, reconstructing, organizing, screening and sharing data, methodologies, and protocols in the fi...
imprint bio

General Information


Serial Number98785816
Word MarkIMPRINT BIO
Filing DateFriday, October 4, 2024
Status645 - FINAL REFUSAL - MAILED
Status DateTuesday, July 29, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


NOT AVAILABLE"BIO"
Goods and ServicesCreating, designing and improving of datasets, namely data analysis, computational modeling, and data compiling for training artificial intelligence (AI) models and large language models (LLM) to learn patterns and make predictions and data models and training data for identifying druggable targets, antibody sequences and cell therapies in the fields of immunology, immunomics, immunotherapy, psychiatry, neurology, allergy, and infectious disease; Providing temporary use of online non-downloadable software for searching, reviewing, analyzing, testing, predicting, inferring, reconstructing, organizing, screening and sharing data, methodologies, and protocols in the fields of immunology, immunomics, immunotherapy, psychiatry, neurology, allergy, and infectious disease; Providing temporary use of online non-downloadable software for searching, reviewing, analyzing, testing, predicting, inferring, reconstructing, organizing, screening and sharing data, methodologies, and protocols in the fields of immunology, immunomics, immunotherapy, psychiatry, neurology, allergy, and infectious disease, namely for generating synthetic or experimental dataset-based digital immune twins; Providing an online database comprising scientific information in the field of immunology, immunomics, immunotherapy, psychiatry, neurology, allergy, and infectious disease collected for training artificial intelligence (AI) models, machine learning models and large language models (LLM) to learn patterns and make predictions; Providing an online database of scientific information in the field of immunology, immunomics, immunotherapy, psychiatry, neurology, cancer, allergy, and infectious disease for generating synthetic or experimental dataset-based digital immune twins; Providing information about methods, namely data analysis, computational modeling, data modeling, machine learning models and training data for training artificial intelligence (AI) models, machine learning models and large language models (LLM) to learn patterns and make predictions for identifying etiology, treatment, and prophylaxis of chronic diseases, autoimmunity, psychiatric, neurological disorders, allergy, and infectious disease; Creating, designing, and building screening, prediction, inference, reconstruction, and analysis platforms and models, namely creation, analysis, and modeling of data to identify pharmaceutical drug targets and biologics candidates for clinical use

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, October 4, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameImprint Labs, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNew York, NY 10014

Trademark Events


Event DateEvent Description
Friday, October 4, 2024NEW APPLICATION ENTERED
Friday, October 4, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 20, 2025ASSIGNED TO EXAMINER
Friday, March 21, 2025NON-FINAL ACTION WRITTEN
Friday, March 21, 2025NON-FINAL ACTION E-MAILED
Friday, March 21, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, June 23, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, June 23, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 29, 2025FINAL REFUSAL WRITTEN
Thursday, October 9, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, October 9, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, September 3, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, June 23, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 29, 2025FINAL REFUSAL E-MAILED
Tuesday, July 29, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, September 3, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, September 3, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED